Louis Island on why clinical governance and unsexy systems will win the race for human longevity

For Louis Island, the real problem with longevity is not curiosity. The problem, as he sees it, is that much of the conversation still mistakes consumption for care. “Longevity will not scale as lifestyle retail; it has to be built as medical-grade prevention.”

Island says this with the clarity of someone who has spent enough time inside the machinery of healthcare to know where the fantasy ends. He is the founder and director of EVRGRN, which helps health and wellness businesses integrate evidence-based longevity medicine into practice, and the COO of MORROW, a Singapore healthspan venture built around personalised longevity care.

What interests him is far less decorative than the current market mood. “When we designed the model of care for the Healthy Longevity Medicine Clinic at Alexandra Hospital, the hardest work was clinical governance and workflow design, not choosing a biomarker panel.” That sentence contains, in miniature, his critique of the field.

Too many operators remain fixated on what can be displayed, packaged and sold. Too few have done the slower, more difficult work of deciding “what claims are acceptable, how diagnostics are used, and how patient safety and data are managed”.

A serious longevity economy, in his view, begins there. It needs “trained physicians, allied health and coaching that can translate diagnostics into practical interventions people can sustain”. It also needs “integrated clinics, accredited diagnostics, and longitudinal data systems that track progress over time, not one-off reports.” None of this sounds sexy, which may be exactly why it matters.

Why systems matter

Island’s language sharpens further when he talks about the mistakes founders and healthcare operators make. “The most common blind spot is building a menu instead of a pathway. A set of tests and devices does not become a programme unless it moves people from assessment, to prioritised intervention, to adherence support, and re-measurement over time.”

In other words, the problem with much of longevity today is not that it lacks innovation. It lacks sequence, discipline, and a coherent route through which a person can actually change.

He is equally unsparing about what consumers now want. The age of the passive patient, at least in this corner of healthcare, has already shifted. What people are paying for, he says, “is not more information, but clinical judgement. Someone who can filter the noise, weigh the trade-offs, and guide them beyond the latest longevity trend circulating on Instagram.” 

This is why Island keeps returning to the same point from different angles. “In reality, it is a care system.” That means “integrated testing, practical intervention, behaviour change support, and continuous feedback”.

It also means that “operational complexity becomes the moat: licensing, governance, risk, privacy, and quality assurance.” He has little patience for founders who treat these as secondary. “If those are bolted on late, scale becomes slow and fragile.”

Mid-life medicine

“Today, longevity medicine sits alongside primary care as a complementary layer.” It fills “the long stretch of midlife when people are largely managing their health alone”. He describes that neglected period with precision: heavy healthcare contact in childhood, then adulthood lived in fragments, then the belated arrival of chronic disease.

Longevity care, at its most credible, steps into that exposed middle with “earlier risk stratification, personalised prevention, and consistent follow-up before disease becomes expensive and difficult to reverse”.

Still, he is under no illusion that logic alone will make prevention scale. “Prevention only scales when the payer captures the upside.” At present, he says, “Most systems reimburse episodes and activity, not long-term risk reduction, so prevention remains something consumers pay for out of pocket.” Without employers, insurers, and governments willing to fund outcomes-based prevention, longevity remains available but not embedded.

He brings the same realism to commercial viability. “You cannot build a business case on human lifespan, so you have to price short-term signals.” The ventures that survive, in his view, are the ones that can show improvement “within months” and keep people engaged “long enough for those gains to compound”.

And if Singapore wants to lead Asia here, Island believes the country already knows the terms of its advantage. “Singapore’s edge is trust and governance, so it should win by becoming the reference market for clinically responsible longevity medicine.”

For him, credibility is key. “If Singapore pairs clear rules with its existing healthcare credibility, it can set standards that others in Asia follow, without needing to be the loudest market in the region.”

Photographer: Angela Guo & Isabelle Cheah
Art direction: Fazlie Hashim
Stylist: Dolphin Yeo